Luca N.
- Country
- Italy
- Department
- Dipartimento di Medicina Sperimentale e Clinica
Research Overview
- Phase II Multicenter Study of Glofitamab Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma After CAR‑T Cell Failure
- Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy
- An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi
Data & Insights
Has run more than one trial at 41 of 137 partner sites.
Specializations
B-Cell Lymphoma Research
This investigator specializes in treating Diffuse Large B-cell Lymphoma (DLBCL), with particular focus on developing therapeutic approaches for elderly and frail patients. Their work explores chemo-free treatment combinations using rituximab-based therapies.
- First-line therapy development
- Treatment strategies for elderly patients
- Refractory DLBCL management
Mantle Cell Lymphoma Studies
The investigator conducts research in Mantle Cell Lymphoma (MCL) treatment, exploring novel therapeutic combinations including BTK inhibitors and targeted therapies. Their work includes assessment of consolidation strategies and combination therapies.
- Novel drug combinations
- Immunotherapy approaches
- Targeted therapeutic strategies
Follicular Lymphoma Innovation
Research interests extend to Follicular Lymphoma treatment, investigating both early-stage and relapsed/refractory disease. The investigator studies novel therapeutic combinations including mosunetuzumab and various targeted agents.
- Radiotherapy combinations
- Immunotherapy development
- Treatment of refractory disease
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.